Head-to-head · free
Doximity, Inc. vs Faeth Therapeutics, Inc.
DOCS vs FTH — return on capital, cash generation, margins and balance sheet side by side.
DOCS
4 / 4
measures where DOCS leads
FTH
0 / 4
measures where FTH leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | DOCS · FY2026 | FTH · FY2025 |
|---|---|---|
| Revenue | $644.9M | — |
| Net income | $196.1M | (21.1M) |
| Revenue growth (yearly, multi-year) | 17.0% | — |
| Free cash flow | $326.5M | (20.5M) |
| Free cash flow margin | 50.6% | — |
| Net cash / (debt) | — | — |
| ROIC | 16.4% | — |
| Return on equity | 19.3% | -74.0% |
| Gross margin | 89.1% | — |
| Operating margin | 33.3% | — |
| Net debt / EBITDA | -0.96x | 0.39x |
Figures are as reported by each company; latest fiscal year shown.
Where Doximity, Inc.'s cash went (FY2026)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Faeth Therapeutics, Inc.'s cash went (FY2025)
- Capital spending
- $16000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free